Lowe Brockenbrough & Co. Inc. Has $951,000 Stake in Eli Lilly and Company (LLY)

Lowe Brockenbrough & Co. Inc. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 1.0% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 11,307 shares of the company’s stock after buying an additional 112 shares during the period. Lowe Brockenbrough & Co. Inc.’s holdings in Eli Lilly and were worth $951,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of LLY. Waldron LP boosted its position in shares of Eli Lilly and by 46.7% during the first quarter. Waldron LP now owns 4,948 shares of the company’s stock worth $415,000 after buying an additional 1,574 shares during the period. BTIM Corp. boosted its position in shares of Eli Lilly and by 9.1% during the first quarter. BTIM Corp. now owns 7,782 shares of the company’s stock worth $655,000 after buying an additional 647 shares during the period. Sigma Planning Corp boosted its position in shares of Eli Lilly and by 3.7% during the first quarter. Sigma Planning Corp now owns 14,385 shares of the company’s stock worth $1,210,000 after buying an additional 512 shares during the period. Rehmann Capital Advisory Group boosted its position in shares of Eli Lilly and by 0.9% during the first quarter. Rehmann Capital Advisory Group now owns 5,026 shares of the company’s stock worth $423,000 after buying an additional 43 shares during the period. Finally, Korea Investment CORP boosted its position in shares of Eli Lilly and by 32.2% during the first quarter. Korea Investment CORP now owns 901,890 shares of the company’s stock worth $75,858,000 after buying an additional 219,539 shares during the period. Institutional investors and hedge funds own 75.77% of the company’s stock.

Eli Lilly and Company (NYSE LLY) traded down 0.74% during trading on Monday, reaching $82.31. 2,060,617 shares of the company’s stock traded hands. The firm’s 50 day moving average is $80.88 and its 200 day moving average is $82.06. The company has a market cap of $86.84 billion, a P/E ratio of 35.62 and a beta of 0.34. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72.

Eli Lilly and (NYSE:LLY) last released its earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion during the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the firm earned $0.86 earnings per share. Analysts anticipate that Eli Lilly and Company will post $4.16 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 8th. Investors of record on Tuesday, August 15th were given a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.51%. The ex-dividend date of this dividend was Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is currently 90.04%.

Several equities analysts have recently issued reports on the company. Berenberg Bank reiterated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Sanford C. Bernstein reiterated an “outperform” rating and set a $88.00 price objective on shares of Eli Lilly and in a research report on Sunday, May 21st. TheStreet downgraded Eli Lilly and from a “b+” rating to a “c” rating in a research report on Wednesday, May 31st. BMO Capital Markets reiterated an “underperform” rating and set a $73.00 price objective on shares of Eli Lilly and in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 price objective for the company. in a research report on Wednesday, July 26th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $88.07.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are reading this news story on another publication, it was illegally stolen and republished in violation of international copyright & trademark legislation. The original version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/11/lowe-brockenbrough-co-inc-has-951000-stake-in-eli-lilly-and-company-lly.html.

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the transaction, the insider now owns 124,265,804 shares of the company’s stock, valued at $10,491,761,831.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last ninety days, insiders sold 825,000 shares of company stock valued at $68,456,650. 0.20% of the stock is owned by insiders.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply